PHARMExcel are delighted to have be selected as INmuneBio’s U.K. CRO to lead on their Phase I clinical trial of INKmune, a novel therapy to prime the patient’s own Natural Killer (NK) cells to attack their cancer, in patients with high-risk Myelodysplastic Syndrome (MDS) (EUDRACT 2019-004820-40). This is a single center, Phase I trial and will…
BACKGROUND PHARMExcel was selected to manage a UK, Phase II, combined Investigational Medicinal Product (IMP)/Medical Device study for COVID-19 patients hospitalised in ICU. We were asked to provide Project Management (PM), Monitoring and Safety oversight for the study, from protocol development to close-out. The study involved two sites and numerous teams responsible for key elements…
PHARMExcel are delighted to be involved in delivering a Covid 19 study in collaboration with Southampton University. We are facilitating fast track approvals and delivery, aiming for site activation by the end of May
